RxDoctor Payments Data

Sonia Preston

Nurse Practitioner · Anniston, ALNPI 1538344619

Payments from drug & device makers

$5,181in general payments, 2019–2025

Across 322 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$2K
  • Merck$509
  • Johnson & Johnson$489
  • Theratechnologies Inc.$165
  • Janssen Products, LP$100
  • plus $106 from 2 others

What the payments were for

  • Food & beverage$5,01697%
  • Education$1653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,181 in reported general payments places this provider in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$11,993
Medicare patients
50
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala716$2,854,403
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf232$1,088,717
DovatoDolutegravir Sodium/Lamivudine333$990,637
JulucaDolutegravir/Rilpivirine156$550,505
TivicayDolutegravir Sodium117$357,937
CabenuvaCabotegravir/Rilpivirine36$229,958
DescovyEmtricitabine/Tenofov Alafenam72$152,147
PrezcobixDarunavir/Cobicistat60$146,556
OdefseyEmtricitab/Rilpiviri/Tenof Ala28$98,678
IsentressRaltegravir Potassium50$87,154
PifeltroDoravirine42$73,420
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$52,024
Darunavir43$50,094
Etravirine30$31,651
Atovaquone19$14,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$1,821$3,058,573801 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Cabenuva$1,993$2,129,036642 claims
Janssen Products, LPSymtuza$100$1,088,717232 claims
MerckIsentress, Pifeltro$509$160,57492 claims
Johnson & JohnsonPrezcobix$489$146,55660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →